DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 781-786

  Pantazopoulos, Dimitrios ^a   Ioakim Liossi, Anna ^a,d   Karakitsos, Petros ^b   Aroni, Kiriaki ^a   Kakoliris, Stilianos ^a   Kanavaros, Panagiotis ^c   Kyrkou, Kalliopi A ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d NONE   (Greece)

Author keywords

Cyclin; DNA ploidy; Proliferating cell nuclear antigen; Superficial transitional cell bladder cancer; WHO grade

Indexed keywords

CYCLINE; DNA;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; FEMALE; FEULGEN STAINING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RISK; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; URINARY BLADDER NEOPLASMS;

EID: 0031059527     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Batatu MA, Chu FC, Hilaris HS et al: Factors on prognostic and therapeutic significance in patients with bladder cancer. Int J Radiol Oncol Biol Phys 7: 575-579, 1981.
2. McCabe RP, Haspel MV, Potanto N, Hunna MG: Monoclonal antibodies in the detection of bladder cancer. In: Cancer diagnosis in vitro using monoclonal antibodies. Vol 39 of Immunology series. (Kupchik HZ, eds) New York: Marcel Dekker, 1988 pp 1-29.
3. Raghavan D, Shipley W, Garnick M et al: Biology and management of bladder cancer. New England Journal of Medicine 322(16): 1129-1138, 1990.
4. Charpin C, Habib MC, Piana L et al: Fraction de croissance (Ki-67), balance de ploidie et index de proliferation dans les tumeurs du tractus urogenital et du sein. Ann Pathol 9: 331-339, 1989.
5. Fontana D, Bellina M, Valenta G et al: L' emploi de 1' anticorps monoclonal Ki-d7 dans 1' etude de 1' activite proliferative des tumeurs urologiques. Donnees preliminaires. J Urol (Paris) 93: 549-552, 1987.
6. Celis JE, Bravo R, Larsen PM, Fey SJ- Cyclins: a nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells. Leukaemia Res 8: 143-157, 1484.
7. Hunter T, Pines J Cyclins and Cancer. Cell 66: 1071-1074, 1991.
8. Mathews MB, Bernstein RM, Franza BR, Garrels JI: Identity of the proliferating cell nuclear antigen and cyclin. Nature 303: 374-376 1484.
9. Ogata K, Kurki P, Celis JE et al: Monoclonal antibody to a nuclear protein (PCNA) associated with DNA replication. Exp Cell Res 168: 475-486, 1987.
10. Glaland P, Degraef C: Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animals and human tissues. Cell Tissue Kinet 22: 383-392, 1989.
11. Lipponen PK, Eskelinen MJ, Cell proliferation of transitional cell bladder cancer determined by PCNA immunostaining. A histopathological description. Anticancer Res 12: 577-583, 1992.
12. Wada T, Shimabukuro T, Kurisu H et al: Expression of proliferating cell nuclear antigen in superficial bladder cancer-application to paraffin-embedded tissue sections. Acta Urol Jap (English Abstract) 39: 313-319, 1993.
13. Skopelitou A, Korkolopoulou P, Papanicolaou A et al: Comparative assessment of proliferating cell nuclear antigen immunostaining and of nuclear organiser region staining in transitional cell carcinomas of the urinary bladder. Europ Urol 22: 235-240, 1992.
14. Jain S, Filipe NI, Hall PA et al: Application of proliferating cell nuclear antigen (PCNA) immunostaining in gastric cancer. J Pathol 161: 351, 1990.
15. Yu CC-W, Hall PA, Fletcher CDM et al: Immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen may be a good indicator of prognosis in haemangiopericytoma. J Pathol 161: 342, 1990.
16. Auer G, Caspersson T, Wallgren A: DNA content and survival in mammary carcinoma. Analyt Quant Cytol 3: 161-165, 1980.
17. Boking A, Striepecke E, Auer H, Fusesi L: Static DNA cytometry In: Compendium on the computerized cytology and histology laboratry. Wied GL, Bartels PH, Rosenthal DL, Schenk U. (Eds), Chicago T.O.C. pp 107-128, 1994.
18. Schapers RF, Ploem-Zaaijer JJ, Pauwels RP et al: Image cytometric analysis in transitional cell carcinoma of the bladder. Cancer 72: 182-189, 1993.
19. Jaskulski D, Gatti G, Travalli S et al: Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase mRNA levels by growth factors. J Biol Chem 263: 10175-10179, 1988.
20. Bravo R, MacDonald-Bravo H: Induction of the nuclear protein cyclin in quiescent mouse 3T3 cells stimulated by serum and growth factors. Correction with DNA synthesis. EMBO J 3: 3177-3181, 1984.
21. Bravo R, MacDonald-Bravo H: Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication. EMBO J 4: 655-661, 1985.
22. Lipponen PK, Eskelinen MJ: Cell proliferation of transitional cell bladder tumours determined by PCNA immunostaining and its prognostic value. Br J Cancer 66: 171-176, 1992.
23. Moris GF, Mathews MB: Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 264: 13856-1386, 1989.
24. Cells JE, Celis A: Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc Natl Acad Sci USA 82: 3262-3266, 1985.
25. Juhl BR, Harzen SH, Hainau B: Lewis an antigen in transitional cell carcinoma of the urinary bladder. Cancer 58: 222-228, 1986.
26. Berger MS, Greenfield C, Gullick WJ et al: Evaluation of epidermal growth factor receptors in bladder tumors. Br J Cancer 56: 533-537 1987.
27. Chauan SS, Goldstein LJ, Gottesman MM: Expression of cathepsin L in human tumors. Cancer Res 51: 1478-1481. 1991.
28. Scharpers RF, Pauwels RPE, Havenith MG et al: Prognostic significance of type IV collagen and laminin immunoreactivity in urothelial carcinomas of the bladder. Cancer 66: 2583-2588, 1991.
29. Al-Abadi H, Borgmann V, Nagel R: Transitional cell carcinoma of the urinary bladder: DNA-cytometric analyses in relation to the grade, stage and clinical course. A follow-up study of 9 years. In: Urology 1992 (Giuliani L, Puppo P, eds.) Bologna: Monduzzi Editore, 1992 pp 429-431.
30. Sun X: Prognostic significance of DNA content in transitional cell carcinoma of the urinary bladder. Chinese journal of oncology (English Abstract) 14: 24-26, 1992.
31. Hofstaedter F, Jakse G, Lederer B, Mikuz G, Delgado R: Biological behaviour and DNA cytophotometry of urothelial bladder carcinoma. Br J Urol 56: 289-295, 1984.
32. van Velthonen R, Petein M, Oosterlinck W, Zandona C, Zlotta A, Adrian P, van der Meijden M, Pasteels J-L, Roels H, Schulman C, Kiss R: Image Cytometry determination of ploidy level, proliferative activity, and nuclear size in a serie of 314 transitional bladder cell carcinomas. Hum Pathol 26: 3-11, 1995.